E
Equillium D
D
EQ
0.34730
USD
-0.04
(-10.00%)
قبل الجلسة
حجم التداول
2,733
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
12,405,319
العنوان: Equillium
القطاع: Healthcare
الصناعة: Biotechnology
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.